Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the five-year survival rates for advanced tumors have ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

Odontogenic myxoma (OM) is a rare benign tumor originating from the odontogenic mesenchyme, characterized by locally aggressive behavior in the jaw bones. We present a case report of a 36-year-old ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s ...